SCHEMBL8103613

SCHEMBL8103613

CC(=O)N[C@@H](CCCCNS(N)(=O)=O)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.80

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 20/20 0.80
HDAC1 Q13547 17/20 0.80
HDAC3 O15379 16/20 0.79
HDAC4 P56524 16/20 0.79
HDAC7 Q8WUI4 16/20 0.79
HDAC2 Q92769 16/20 0.79
HDAC10 Q969S8 16/20 0.79
HDAC11 Q96DB2 16/20 0.79
HDAC8 Q9BY41 16/20 0.79
HDAC9 Q9UKV0 16/20 0.79
HDAC5 Q9UQL6 16/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5327667 0.92 HDAC6 (0.82) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL5328254 0.91 HDAC6 (0.81) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL8119260 0.91 HDAC6 (0.79) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL5468800 0.91 HDAC6 (0.85) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL5468805 0.91 HDAC6 (0.85) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL5330036 0.89 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL5330042 0.89 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL5459414 0.88 HDAC6 (0.73) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL8118753 0.88 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC4HDAC7
SCHEMBL5324599 0.88 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HAT1 HDAC6 11/4885HDAC1 1/4885HDAC3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.